Watchlist

Watchlist
Anavex Life Sciences Corp. (AVXL)
Anavex Life Sciences Corp. (AVXL)
Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, …
Anavex Life Sciences Corp's (AVXL) CEO Christopher Missling on Q1 2018 Results - Earnings Call Transcript
Anavex Life Sciences Corp (AVXL) Q1 2018 Earnings Conference Call May 10, 2018, 16:30 ET Executives Meggie Purcell - IR Christopher Missling - Chairman, President, CEO & Secretary Sandra Boenisch - Principal Financial Officer & Treasurer Analysts Robert LeBoyer - Ro…
Anavex Life Sciences misses by $0.01
Anavex Life Sciences (NASDAQ: AVXL ): Q2 EPS of -$0.11 misses by $0.01 . Cash and equivalents of $25.7M Press Release More news on: Anavex Life Sciences Corp., Earnings news and commentary, Healthcare stocks news, ,
Healthcare - Top 5 Gainers / Losers as of 11:00 AM (04/23/2018)
Gainers: CHEK +14% . INSM +9% . EBIO +8% . AKCA +7% . AVXL +6% . More news on: Check-Cap Ltd., Insmed, Inc., Eleven Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more …
Premarket Losers as of 9:05 am (4/17/2018)
LADR -9% . More news on: Ladder Capital Corp, Bellicum Pharmaceuticals, Anavex Life Sciences Corp., Stocks on the move, , Read more …
Anavex readies mid-stage study of lead candidate in PDD; shares ahead 2% premarket
Anavex Life Sciences (NASDAQ: AVXL ) is up 2% premarket on average volume in response to its announcement that it plans to initiate a Phase 2 clinical trial evaluating lead candidate ANAVEX 2-73 in patients with Parkinson's Disease Dementia (PDD). The study should launch in H2….
Oryzon Genomics on go with mid-stage study of Alzheimer's candidate ORY-2001
Madrid, Spain-based Oryzon Genomics announces that it has received regulatory sign-off for a Phase 2a clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: Alzheon, Denali Therapeutics, Inc., Wave Life Sciences, Healthcare stocks news…
Anavex 2-73 And The Stabilization Of Alzheimer's Disease
Despite the limitations of Anavex's ( AVXL ) current trial, there are a number of reasons to remain optimistic about the potential of Anavex 2-73 to treat Alzheimer's disease and to be confident about the company's long-term future. At high concentrations, Anavex 2-73 appears to lead to some…
Premarket analyst action - healthcare
Cowen, Barclays and ROTH all host healthcare conferences next week. More news on: Anavex Life Sciences Corp., Owens & Minor Inc., Verastem, Inc., Healthcare stocks news, Stocks on the move, Read more …
Biogen, Neurotrope, Anavex And The Future Of Alzheimer's Treatments
There are basically two approaches to Alzheimers research: the traditional and the non-traditional. The traditional approach focuses on preventing the formation or removing misfolded proteins: amyloid and tau. The non-traditional approach focuses on ameliorating other aspects of Alzhei…
Anavex Life Sciences Corp. (AVXL)